keyword
MENU ▼
Read by QxMD icon Read
search

Prostate cancer survival

keyword
https://www.readbyqxmd.com/read/28103576/a-new-model-of-multi-visceral-and-bone-metastatic-prostate-cancer-with-perivascular-niche-targeting-by-a-novel-endothelial-specific-adenoviral-vector
#1
Zhi Hong Lu, Sergey Kaliberov, Rebecca E Sohn, Lyudmila Kaliberova, Yingqiu Du, Julie L Prior, Daniel J Leib, Anne Chauchereau, Jennifer K Sehn, David T Curiel, Jeffrey M Arbeit
While modern therapies for metastatic prostate cancer (PCa) have improved survival they are associated with an increasingly prevalent entity, aggressive variant PCa (AVPCa), lacking androgen receptor (AR) expression, enriched for cancer stem cells (CSCs), and evidencing epithelial-mesenchymal plasticity with a varying extent of neuroendocrine transdifferentiation. Parallel work revealed that endothelial cells (ECs) create a perivascular CSC niche mediated by juxtacrine and membrane tethered signaling. There is increasing interest in pharmacological metastatic niche targeting, however, targeted access has been impossible...
January 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28101887/abiraterone-or-enzalutamide-in-advanced-castration-resistant-prostate-cancer-an-indirect-comparison
#2
Akhil Chopra, Mina Georgieva, Gilberto Lopes, Chong Ming Yeo, Benjamin Haaland
BACKGROUND: To perform a comparative effectiveness analyses between enzalutamide and abiraterone acetate in both the pre-docetaxel and post-docetaxel settings based on published phase III randomized trials. METHODS: The primary measure of efficacy was the posterior probability that enzalutamide outperforms abiraterone acetate (AA) with prednisone in terms of overall survival (OS) on average. Indirect meta-estimates were generated from four randomized studies in the context of a Bayesian hierarchical model with study-specific efficacy estimates meta-analyzed on the log scale...
January 19, 2017: Prostate
https://www.readbyqxmd.com/read/28101585/whole-pelvis-radiotherapy-for-pathological-node-positive-prostate-cancer-oncological-outcome-and-prognostic-factors
#3
Filip Poelaert, Valérie Fonteyne, Piet Ost, Bart De Troyer, Karel Decaestecker, Gert De Meerleer, Pieter De Visschere, Tom Claeys, Bert Dhondt, Nicolaas Lumen
PURPOSE: The goal of this work was to investigate the oncological outcome of whole pelvis radiotherapy (wpRT) in pathologic pelvic lymph node-positive (pN1) prostate cancer (PCa), evaluate the location of relapse, and identify potential prognostic factors. PATIENTS AND METHODS: All patients undergoing pelvic lymph node dissection (PLND) since the year 2000 at a single tertiary care center were evaluated. A total of 154 patients with pN1 PCa were treated with wpRT (39 in an adjuvant setting) and 2-3 years of androgen deprivation therapy (ADT)...
January 18, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28099688/discerning-the-survival-advantage-among-patients-with-prostate-cancer-who-undergo-radical-prostatectomy-or-radiotherapy-the-limitations-of-cancer-registry-data
#4
Stephen B Williams, Jinhai Huo, Karim Chamie, Marc C Smaldone, Christopher D Kosarek, Justin E Fang, Leslie M Ynalvez, Simon P Kim, Karen E Hoffman, Sharon H Giordano, Brian F Chapin
BACKGROUND: The objective of this study was to compare the overall survival of patients who undergo radical prostatectomy or radiotherapy versus noncancer controls to discern whether there is a survival advantage according to prostate cancer treatment and the impact of selection bias on these results. METHODS: A matched cohort study was performed using the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database. In total, 34,473 patients ages 66 to 75 years were identified who were without significant comorbidity, were diagnosed with localized prostate cancer, and received treatment treated with surgery or radiotherapy between 2004 and 2011...
January 18, 2017: Cancer
https://www.readbyqxmd.com/read/28098061/prostate-cancer-immunotherapy-particularly-in-combination-with-androgen-deprivation-or-radiation-treatment-customized-pharmacogenomic-approaches-to-overcome-immunotherapy-cancer-resistance
#5
REVIEW
C Alberti
Conventional therapeutic approaches for advanced prostate cancer - such as androgen deprivation, chemotherapy, radiation - come up often against lack of effectiveness because of possible arising of correlative cancer cell resistance and/or inadequate anti-tumor immune conditions. Whence the timeliness of resorting to immune-based treatment strategies including either therapeutic vaccination-based active immunotherapy or anti-tumor monoclonal antibody-mediated passive immunotherapy. Particularly attractive, as for research studies and clinical applications, results to be the cytotoxic T-lymphocyte check point blockade by the use of anti-CTLA-4 and PD-1 monoclonal antibodies, particularly when combined with androgen deprivation therapy or radiation...
September 2017: Il Giornale di Chirurgia
https://www.readbyqxmd.com/read/28097317/surrogate-end-points-for-all-cause-mortality-in-men-with-localized-unfavorable-risk-prostate-cancer-treated-with-radiation-therapy-vs-radiation-therapy-plus-androgen-deprivation-therapy-a-secondary-analysis-of-a-randomized-clinical-trial
#6
Trevor J Royce, Ming-Hui Chen, Jing Wu, Marian Loffredo, Andrew A Renshaw, Philip W Kantoff, Anthony V D'Amico
Importance: Several surrogates for prostate cancer-specific mortality satisfying the Prentice criteria exist, but whether these are surrogates for all-cause mortality, and how their performance compares, is unknown. Objective: To ascertain and compare the performance of 4 candidate surrogates (prostate-specific antigen [PSA] failure, PSA nadir >0.5 ng/mL, PSA doubling time <9 months, and interval to PSA failure <30 months) for all-cause mortality using the proportion of treatment-effect metric...
January 12, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28097263/predicting-biochemical-recurrence-in-patients-with-high-risk-prostate-cancer-using-the-apparent-diffusion-coefficient-of-magnetic-resonance-imaging
#7
Min Young Yoon, Juhyun Park, Jeong Yeon Cho, Chang Wook Jeong, Ja Hyeon Ku, Hyeon Hoe Kim, Cheol Kwak
PURPOSE: We aimed to investigate whether the apparent diffusion coefficient (ADC) value in diffusion-weighted magnetic resonance imaging predicts the prognoses of patients with high-risk prostate cancer. MATERIALS AND METHODS: A total of 157 patients with high-risk prostate cancer (based on D'Amico's criteria) were included in the analysis. Patients underwent preoperative 3.0 Tesla magnetic resonance imaging within 2 months before radical prostatectomy. Those who received neoadjuvant hormone therapy (33 persons) or radiation therapy (18 persons) were excluded...
January 2017: Investigative and Clinical Urology
https://www.readbyqxmd.com/read/28096932/contemporary-agents-in-the-management-of-metastatic-castration-resistant-prostate-cancer
#8
REVIEW
Anil Kapoor, Christopher Wu, Bobby Shayegan, Adrian P Rybak
Docetaxel-based chemotherapy has been the standard of care for metastatic castration-resistant prostate cancer (mCRPC) since 2004. Over the past few years, there has been a significant paradigm shift in the treatment landscape of this disease. A deeper understanding of prostate cancer biology, along with the development of novel agents has created hope towards treating chemotherapy-naïve and resistant disease. Following the implementation of docetaxel as the first-line therapy for mCRPC, five novel therapies have demonstrated survival benefit in mCRPC...
November 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28096199/trends-in-radiation-therapy-among-cancer-survivors-in-the-united-states-2000-2030
#9
Alex K Bryant, Matthew Banegas, Maria E Martinez, Loren K Mell, James D Murphy
BACKGROUND: Although the number of cancer survivors has increased substantially over the past several decades, the composition of survivors treated with radiotherapy is not well defined. Radiotherapy carries unique long-term toxicity risks for cancer survivors. This study describes the current estimates and future projections of the epidemiology of five-year cancer survivors who receive radiation therapy. METHODS: We used cancer incidence and survival data from the Surveillance, Epidemiology, and End-Results (SEER) database linked to US Census data to estimate the number of five-year cancer survivors treated with radiation between 2000 and 2030...
January 17, 2017: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/28096182/treatment-of-locally-advanced-prostate-cancer-stage-t3
#10
Yoshiyasu Amiya, Yasutaka Yamada, Masahiro Sugiura, Makoto Sasaki, Takayuki Shima, Noriyuki Suzuki, Hiroomi Nakatsu, Shino Murakami, Jun Shimazaki
OBJECTIVE: Formerly, locally advanced prostate cancer exhibited poorly prognosis. In the late 1990s, new surgical and radiation technologies were introduced in combination with androgen deprivation. To evaluate respective strategies, outcomes were examined. PATIENTS AND METHODS: Between 2001 and 2010, 224 patients with T3N0M0 (10.9% of all prostate cancer cases) were treated with prostatectomy, external beam radiation therapy with/without androgen deprivation or hormone alone...
January 17, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28095710/the-evolving-role-of-chemotherapy-in-prostate-cancer
#11
Suliman Boulos, Danish Mazhar
Despite extensive clinical research of different chemotherapy agents for more than three decades, the role of chemotherapy in prostate cancer was only established in 2004, after demonstrating a survival benefit with docetaxel in metastatic castration-resistant prostate cancer. 6 years later, second-line chemotherapy using cabazitaxel, after disease progression on docetaxel, demonstrated an additional survival improvement. Recently, docetaxel given alongside standard hormonal therapy in newly diagnosed advanced prostate cancer was found to lead to significantly improved patient outcomes...
January 18, 2017: Future Oncology
https://www.readbyqxmd.com/read/28094250/end-of-radiation-psa-as-a-novel-prognostic-factor-in-patients-undergoing-definitive-radiation-and-androgen-deprivation-therapy-for-prostate-cancer
#12
A K Narang, J Trieu, N Radwan, A Ram, S P Robertson, P He, C Gergis, E Griffith, H Singh, T A DeWeese, S Honig, A Annadanam, S Greco, C DeVille, T McNutt, T L DeWeese, D Y Song, P T Tran
BACKGROUND: In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS: Prostate cancer patients consecutively treated with definitive radiation at our institution by a single provider from 1993 to 2006 and who had an end-of-radiation (EOR) PSA (n=688, median follow-up 11.2 years). We analyzed the association of an EOR PSA level, obtained during the last week of radiation, with survival outcomes...
January 17, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28093792/prognostic-role-of-preoperative-serum-lipid-levels-in-patients-undergoing-radical-prostatectomy-for-clinically-localized-prostate-cancer
#13
Marian S Wettstein, Karim Saba, Martin H Umbehr, Teemu J Murtola, Christian D Fankhauser, Jean-Pascal Adank, Marc Hofmann, Tullio Sulser, Thomas Hermanns, Holger Moch, Peter Wild, Cédric Poyet
BACKGROUND: The prognostic role of preoperative serum lipid levels in patients undergoing radical prostatectomy (RP) for clinically localized prostate cancer (PCa) is unclear. The aim of the present study was to investigate preoperative serum lipid levels in patients with clinically localized PCa undergoing RP and their association with clinicopathological features and oncological outcome. METHODS: Preoperative lipid levels (total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides) and statin use from consecutive patients with clinically localized PCa undergoing RP in a tertiary referral center between 2008 and 2015 were recorded and patients were followed prospectively...
January 17, 2017: Prostate
https://www.readbyqxmd.com/read/28093791/local-therapy-improves-overall-survival-in-patients-with-newly-diagnosed-metastatic-prostate-cancer
#14
Rahul R Parikh, John Byun, Sharad Goyal, Isaac Yi Kim
BACKGROUND: The role of local therapy, in the form of radiation therapy (RT) or radical prostatectomy(RP), and its association on outcomes is not well established in patients with metastatic prostate cancer. METHODS: Using the National Cancer Database (NCDB), we evaluated patterns of care and outcomes among patients diagnosed with metastatic prostate cancer from 2004 to 2013 treated with local therapy (RP, intensity-modulated radiation therapy [IMRT], or 2D/3D-conformal radiation therapy [CRT])...
January 17, 2017: Prostate
https://www.readbyqxmd.com/read/28089230/metastatic-fractures-of-long-limb-bones
#15
REVIEW
P Anract, D Biau, P Boudou-Rouquette
The diagnosis of pathological fracture should be considered routinely in patients with long limb-bone fractures. Investigations must be performed to establish the diagnosis of pathological fracture then to determine that the bone lesion is a metastasis. In over 85% of cases, the clinical evaluation combined with a detailed analysis of the radiographs is sufficient to determine that the fracture occurred at a tumour site. Aetiological investigations establish that the tumour is a metastasis. In some patients, the diagnosis of metastatic cancer antedates the fracture...
January 11, 2017: Orthopaedics & Traumatology, Surgery & Research: OTSR
https://www.readbyqxmd.com/read/28088885/-androgen-receptor-mediated-processes-in-castrate-resistant-metastatic-prostate-cancer
#16
Zsófia Küronya, Krisztina Bíró, Fruzsina Gyergyay, Lajos Géczi
In the past six years, five new drugs have been approved by the FDA for the treatment of metastatic castrate-resistant prostate cancer. While the disease itself still remains incurable, the sequential use of these drugs can significantly prolong survival while maintaining good quality of life. Research from the past decade made it clear that androgen receptor-mediated processes play a central part in the progression of the disease. Hormonal mechanisms related to androgen-receptors can remain active until late stages of the disease...
January 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/28077413/cancer-related-hospitalisations-and-unknown-stage-prostate-cancer-a-population-based-record-linkage-study
#17
Qingwei Luo, Xue Qin Yu, David Paul Smith, David Eamon Goldsbury, Claire Cooke-Yarborough, Manish Indravadan Patel, Dianne Lesley O'Connell
OBJECTIVES: To identify reasons for prostate cancer stage being recorded as 'unknown' in Australia's largest population-based cancer registry. DESIGN: Prospective population-based cohort. SETTING: New South Wales (NSW) is the most populous state in Australia, with almost one third of the total national population. PARTICIPANTS: NSW Cancer Registry (NSWCR) records for prostate cancer cases diagnosed in 2001-2009 were linked to the NSW Admitted Patient Data Collection (APDC) for 2000-2010...
January 11, 2017: BMJ Open
https://www.readbyqxmd.com/read/28077128/treatment-planning-comparison-of-impt-vmat-and-4%C3%AF-radiotherapy-for-prostate-cases
#18
Angelia Tran, Jingjing Zhang, Kaley Woods, Victoria Yu, Dan Nguyen, Gary Gustafson, Lane Rosen, Ke Sheng
BACKGROUND: Intensity-modulated proton therapy (IMPT), non-coplanar 4π intensity-modulated radiation therapy (IMRT), and volumetric-modulated arc therapy (VMAT) represent the most advanced treatment methods based on heavy ion and X-rays, respectively. Here we compare their performance for prostate cancer treatment. METHODS: Ten prostate patients were planned using IMPT with robustness optimization, VMAT, and 4π to an initial dose of 54 Gy to a clinical target volume (CTV) that encompassed the prostate and seminal vesicles, then a boost prescription dose of 25...
January 11, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28077116/quality-of-life-and-functional-outcome-after-infravesical-desobstruction-and-hifu-treatment-for-localized-prostate-cancer
#19
G Hatiboglu, I V Popeneciu, M Deppert, J Nyarangi-Dix, B Hadaschik, M Hohenfellner, D Teber, S Pahernik
BACKGROUND: To evaluate quality of life, functional and oncological outcome after infravesical desobstruction and HIFU treatment for localized prostate cancer. METHODS: One hundred thirty-one patients, treated with TURP and HIFU in a single institution were followed up for oncological and functional outcome. Oncological outcome was quantified by biochemical recurrence free survival using the Stuttgart and Phoenix criteria. Quality of life was assessed by usage of standardized QLQ-C30 and QLQ-PR25 questionnaires...
January 11, 2017: BMC Urology
https://www.readbyqxmd.com/read/28075160/can-we-accomplish-better-oncological-results-with-robot-assisted-radical-prostatectomy
#20
Ali Riza Kural, Can Obek, Tünkut Doğanca
Surgical removal with radical prostatectomy has been a cornerstone for the treatment of prostate cancer and is associated with level one evidence for survival advantage compared to watchful waiting. Since the first structured robotic program was launched in 2000, robot-assisted radical prostatectomy (RARP) has had a rapid diffusion and surpassed its open (ORP) and laparoscopic (LRP) counterparts in the United States and is progressively expanding in other countries. Interestingly, this common acceptance of RARP was initially driven in the paucity of robust clinical evidence...
January 11, 2017: Journal of Endourology
keyword
keyword
8536
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"